95 related articles for article (PubMed ID: 22574619)
1. The language of prostate cancer treatments and implications for informed decision making by patients.
Rot I; Ogah I; Wassersug RJ
Eur J Cancer Care (Engl); 2012 Nov; 21(6):766-75. PubMed ID: 22574619
[TBL] [Abstract][Full Text] [Related]
2. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
4. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
[TBL] [Abstract][Full Text] [Related]
5. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
6. The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy.
Nyman CR; Andersen JT; Lodding P; Sandin T; Varenhorst E
BJU Int; 2005 Nov; 96(7):1014-8. PubMed ID: 16225519
[TBL] [Abstract][Full Text] [Related]
7. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
Scherr DS; Pitts WR
J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
[TBL] [Abstract][Full Text] [Related]
8. Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy.
Sevilla C; Maliski SL; Kwan L; Connor SE; Litwin MS
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):237-43. PubMed ID: 22289781
[TBL] [Abstract][Full Text] [Related]
9. Information needs of men on androgen deprivation therapy.
Soeyonggo T; Warde P; Fleshner N; Timilshina N; Alibhai SM
BJU Int; 2012 May; 109(10):1503-9. PubMed ID: 21883845
[TBL] [Abstract][Full Text] [Related]
10. Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
Takizawa I; Hara N; Nishiyama T; Isahaya E; Hoshii T; Takahashi K
J Urol; 2010 Nov; 184(5):1971-6. PubMed ID: 20884032
[TBL] [Abstract][Full Text] [Related]
11. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy.
Herr HW; O'Sullivan M
J Urol; 2000 Jun; 163(6):1743-6. PubMed ID: 10799173
[TBL] [Abstract][Full Text] [Related]
12. Life after failure of traditional androgen deprivation therapy.
Schellhammer P
Urol Oncol; 2012; 30(4 Suppl):S10-4. PubMed ID: 22795075
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy for prostate cancer: the role of hormonal treatment.
Shahani R; Fleshner NE; Zlotta AR
Discov Med; 2007 Aug; 7(39):118-24. PubMed ID: 18093474
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.
Baade PD; Youlden DR; Gardiner RA; Ferguson M; Aitken JF; Yaxley J; Chambers SK
BJU Int; 2012 Dec; 110(11 Pt B):E712-9. PubMed ID: 23017157
[TBL] [Abstract][Full Text] [Related]
15. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Cherrier MM; Rose AL; Higano C
J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
[TBL] [Abstract][Full Text] [Related]
16. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
17. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
18. [First line therapy in the treatment of metastatic prostate cancer].
Sakai H; Kanetake H
Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
[TBL] [Abstract][Full Text] [Related]
19. Managing prostate cancer: the role of hormone therapy.
Ramirez ML; Keane TE; Evans CP
Can J Urol; 2007 Dec; 14 Suppl 1():10-8. PubMed ID: 18163939
[TBL] [Abstract][Full Text] [Related]
20. Novel agents for the management of castration-resistant prostate cancer.
Haddad H; Garcia JA
Curr Opin Urol; 2012 May; 22(3):175-82. PubMed ID: 22472509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]